ArticleAmerican journal of cancer research2024

Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study.

Chao Li et al.PubMed ↗Full text ↗

No numbers read from the abstract.